Drug Trial Radar · NCT05305664
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Aug 19, 2022
Primary completion
Jan 28, 2025
Study completion Jan 28, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.
Conditions
- Hyperlipoproteinemia(a)
Interventions
Pelacarsen (TQJ230) 80 mg s.c.Drug
Pelacarsen (TQJ230) 80 mg s.c. Q4W
Corresponding PlaceboDrug
Placebo to Pelacarsen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis ScheduleTime frame: Up to Week 52
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Cloppenburg, Germany
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Villingen-Schwenningen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Geilenkirchen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.